MYSTIC - A Phase III, randomized, open-label study of Durvalumab (MEDI4736) in combination with Tremelimumab or Durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced stage IV non small cell lung cancer (aNSCLC): A German update
2017
Keywords:
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
0
References
4
Citations
NaN
KQI